单独或联合免疫疗法治疗肝癌的研究进展  

Research progress of immunotherapy alone and in combination for liver cancer

作　　者：吴周姜丽 李凯 张楷 龚伟达[2,3] Wu Zhoujiangli;Li Kai;Zhang Kai;Gong Weida(Department of General Surgery,Yixing Cancer Hospital,Wuxi 214205,China;Department of General Surgery,Yixing Hospital Affiliated to Jiangsu University,Wuxi 214200,China;Department of General Surgery,People's Hospital of Yixing City,Wuxi 214200,China)

机构地区：[1]江苏省宜兴市肿瘤医院普外科,无锡214205 [2]江苏大学附属宜兴医院普外科,无锡214200 [3]江苏省宜兴市人民医院普外科,无锡214200

出　　处：《中华肝脏病杂志》2020年第6期471-474,共4页Chinese Journal of Hepatology

基　　金：国家卫生计生委科研项目(W2015PM113)。

摘　　要：目前,肝细胞肝癌(HCC)在我国常见恶性肿瘤中发病率排第四位,病死率排第二位。现阶段HCC临床治疗首选方法是早期手术切除,但大多数患者确诊时已至中晚期,此时手术已无法进行,而传统的放、化疗等手段预后较差,不良反应较多,这使目前我国HCC的临床治疗充满挑战,急需新的治疗策略来改善肝癌患者的生存质量。随着现代医学的进步,HCC的治疗方式已不再局限于传统的治疗手段,免疫疗法作为一种新兴治疗方式已经成为HCC的重要治疗手段。近年来,HCC的免疫治疗和新型靶向药物成为研究的热点,并且在HCC的治疗中已取得了很多成果,现就近年来单独或联合免疫疗法治疗HCC的现状与进展作一简要综述。Presently,the incidence of hepatocellular carcinoma(HCC)ranks fourth among common malignant tumors in China,and the mortality rate ranks second.The preferred method of clinical treatment for HCC is early surgical resection at this time,but most patients have reached to mid-advanced stage at the time of diagnosis,so surgery cannot be performed.Traditional radiotherapy and chemotherapy have poor prognosis and many adverse reactions,which make the current clinical treatment of HCC in China full of challenges.Therefore,new treatment strategies are urgently needed to improve the quality of life of liver cancer patients.With the advancement of modern medicine,the treatment of liver cancer is no longer limited to traditional treatments.Immunotherapy as a new treatment has become an important treatment for liver cancer.In recent years,immunotherapy and new targeted drugs for liver cancer have become a research hotspot,and many achievements have been made in the treatment of liver cancer.In this paper,the current situation and progress of single or combined immunotherapy for liver cancer of recent years are briefly reviewed.

关 键 词：肝细胞癌 免疫治疗 免疫检查点抑制剂 联合疗法 

分 类 号：R735.7[医药卫生—肿瘤]